51.90
-1.90 (-3.53%)
| Previous Close | 53.80 |
| Open | 52.45 |
| Volume | 8,707 |
| Avg. Volume (3M) | 4,885 |
| Market Cap | 559,995,840 |
| 52 Weeks Range | |
| Earnings Date | 19 Aug 2025 |
| Profit Margin | 37.21% |
| Operating Margin (TTM) | 39.46% |
| Diluted EPS (TTM) | -0.580 |
| Quarterly Revenue Growth (YOY) | 81.80% |
| Quarterly Earnings Growth (YOY) | -34.90% |
| Total Debt/Equity (MRQ) | 137.87% |
| Current Ratio (MRQ) | 4.85 |
| Operating Cash Flow (TTM) | 74.36 M |
| Levered Free Cash Flow (TTM) | 48.68 M |
| Return on Assets (TTM) | 17.89% |
| Return on Equity (TTM) | 218.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (GB) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | BASILEA PHARMACEUTICA AG BASILE | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -0.5 |
| Average | -0.13 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| BASILEA PHARMACEUTICA AG BASILE | 560 M | - | - | - |
| ARROWHEAD PHARMACEUTICALS INC A | 2 B | - | - | - |
| RELIEF THERAPEUTICS HOLDING SA | 2 B | - | - | - |
| IDORSIA LTD IDORSIA N ORD SHS | 1 B | - | - | - |
| OXFORD NANOPORE TECHNOLOGIES PL | 1 B | - | - | 2.97 |
| IOVANCE BIOTHERAPEUTICS INC IOV | 401 M | - | - | - |
|
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.25% |
| % Held by Institutions | 31.15% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |